Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Salubris gets Chinese rights to Viracta's nanatinostat

Executive Summary

Viracta Therapeutics Inc. granted Shenzhen Salubris Pharmaceuticals Co. Ltd. exclusive rights to develop and sell its virus-related cancer therapy nanatinostat/valganciclovir in the Peoples Republic of China (excluding Hong Kong, Macau, and Taiwan).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information

Related Companies

UsernamePublicRestriction

Register